You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AC5 Inhibitor for Obesity

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a gl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A device containing an immobilized chelator to remove aluminum from total parente

    SBC: ALKYMOS, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): A high percentage of the ~ 500,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common contam ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced Cannula Development for Coronary Sinus Access

    SBC: STRATEGIC PACING SYSTEMS LLC            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase STTR will develop novel techniques for coronary sinus access The coronary sinus provides unique anatomic and physiologic proximity to all four cardiac chambers and the coronary circulation For example the coronary sinus is used for left ventricular lead insertion for biventricular pacing or cardiac resynchronization Mor than such implan ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An Advanced Biosensor for Molecular Interaction Studies

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions are central to the understanding of basic biology and cellular function, are paramount to all molecular assays (research and in vitro diagnostics), are essential in biomarker discovery and critical toward evaluating therapeutics. However, the tools available to quantify these interactions have limitations, in so far as they either rely up ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates

    SBC: APOIMMUNE, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic use of general immunosuppression. This approach, terme ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Cancer Imaging and Therapy Platform

    SBC: BIOINVISION INC            Topic: 102

    Summary We will create a preclinical quantitative Cancer Imaging and Therapy Platform CITP which will allow one to study cancer biology and optimize pipelines of technologies imaging agents imaging methods targeted nano therapeutics tumor models etc especially for metastatic and invasive cancers Today primary tumor mass es are clinically controlled with surgical drug and radiatio ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

    SBC: ATHERSYS, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This is a resubmission of a Phase I Phase II Fast Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome ARDS ARDS is defined as acute onset hypoxemia bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension A novel and exiting possibility is the use of cells as part of the ther ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Commercialization of a Diagnostic Test for Alzheimer's Disease

    SBC: SCOUT DIAGNOSTICS            Topic: NIA

    DESCRIPTION (provided by applicant): The major barriers to preventing or treating Alzheimer's disease (AD) are its unknown pathogenesis/etiology and the lack of an objective, sensitive and specific biomarker of the disease, particularly at the early stages when therapeutic interventions would likely have the greatest efficacy. The basic hypothesis of this project is that levels of a unique high mo ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government